<p>Our study was designed to identify biomarkers related to the prognosis of Pancreatic Ductal AdenoCarcinoma (PDAC) patients using genomic variants and gene expression in coding regions of the human genome (exome). PDAC is the 7th cause of cancer deaths and is among types of cancer having the poorest prognosis. To improve treatment outcomes of PDAC, biomarkers related to PDAC prognosis are needed. The goals of our study are to find genomic and transcriptomic biomarkers, which can classify prognosis subtype of PDAC patients, and eventually to predict subtypes or prognosis for each patient. In this study, we generated Whole Exome Sequencing (WES) and exome capture RNA sequencing data of 450 tumor and matched normal samples from 150 PDAC patients. Our data may be useful for understanding genomic and transcriptomic features, prognosis prediction, and precision medicine for PDAC.</p>

PDAC Prognosis Biomarkers in Genomic and Transcriptomic Molecular Data

Carcinoma, Pancreatic Ductal study with RNA-Seq, SNP Genotypes (NGS) + 2 more data on dbGaP (150 participants)

PDAC Prognosis Biomarkers in Genomic and Transcriptomic Molecular Data

Description

Applying For Access

Summary